JP2005508371A5 - - Google Patents

Download PDF

Info

Publication number
JP2005508371A5
JP2005508371A5 JP2003541826A JP2003541826A JP2005508371A5 JP 2005508371 A5 JP2005508371 A5 JP 2005508371A5 JP 2003541826 A JP2003541826 A JP 2003541826A JP 2003541826 A JP2003541826 A JP 2003541826A JP 2005508371 A5 JP2005508371 A5 JP 2005508371A5
Authority
JP
Japan
Prior art keywords
food supplement
composition
amount
pharmaceutical
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003541826A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005508371A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/031987 external-priority patent/WO2003039535A1/en
Publication of JP2005508371A publication Critical patent/JP2005508371A/ja
Publication of JP2005508371A5 publication Critical patent/JP2005508371A5/ja
Pending legal-status Critical Current

Links

JP2003541826A 2001-10-05 2002-10-07 インスリン抵抗性症候群の症状を予防するかまたは低下させるための方法と組成物 Pending JP2005508371A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32789601P 2001-10-05 2001-10-05
PCT/US2002/031987 WO2003039535A1 (en) 2001-10-05 2002-10-07 Method and composition for preventing or reducing the symptoms of insulin resistance syndrome

Publications (2)

Publication Number Publication Date
JP2005508371A JP2005508371A (ja) 2005-03-31
JP2005508371A5 true JP2005508371A5 (enExample) 2005-12-22

Family

ID=23278548

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003541826A Pending JP2005508371A (ja) 2001-10-05 2002-10-07 インスリン抵抗性症候群の症状を予防するかまたは低下させるための方法と組成物

Country Status (9)

Country Link
US (3) US7119110B2 (enExample)
EP (1) EP1438038A4 (enExample)
JP (1) JP2005508371A (enExample)
AU (1) AU2002351456B2 (enExample)
CA (1) CA2462158A1 (enExample)
IL (1) IL161186A0 (enExample)
MX (1) MXPA04003233A (enExample)
WO (1) WO2003039535A1 (enExample)
ZA (1) ZA200402688B (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1011660A1 (en) 1997-07-14 2000-06-28 Inter-Health Nutraceuticals Incorporated Hydroxycitric acid compositions, pharmaceutical and dietary supplements and food products made therefrom, and methods for their use in reducing body weight
US20040157929A1 (en) * 2002-04-01 2004-08-12 Ohia Sunny E. Method for increasing serotonin levels in a person by administration of a composition incorporating(-)hydroxycitric acid, and related compositions thereof
US7119110B2 (en) 2001-10-05 2006-10-10 Interhealth Nutraceuticals Incorporated Method and composition for preventing or reducing the symptoms of insulin resistance syndrome
US20030119913A1 (en) * 2001-12-20 2003-06-26 Ohia Sunny E. Method for increasing serotonin levels in a person by administration of a composition incorporating (-)-hydroxycitric acid, and related compositions thereof
ES2283756T3 (es) * 2002-03-01 2007-11-01 Novagali Pharma Sa Sistemas autoemulsionantes de administracion de farmaco para taxoides.
US7977049B2 (en) * 2002-08-09 2011-07-12 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
WO2004085462A2 (en) * 2003-03-21 2004-10-07 Interhealth Nutraceuticals Incorporated Method and composition for decreasing ghrelin levels
US20050096256A1 (en) * 2003-07-01 2005-05-05 President And Fellows Of Harvard College Compositions for manipulating the lifespan and stress response of cells and organisms
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
EP1708689A2 (en) * 2003-12-29 2006-10-11 The President and Fellows of Harvard College Compositions for treating or preventing obesity and insulin resistance disorders
ES2390075T3 (es) 2004-03-19 2012-11-06 Institut Pasteur Péptidos derivados de la proteína BPLP humana, polinucleótidos que codifican dichos péptidos y anticuerpos dirigidos contra dichos péptidos
US20050215644A1 (en) * 2004-03-19 2005-09-29 Interhealth Nutraceuticals, Inc. Methods for increasing neurotransmitter levels using hydroxycitric acid
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
US20060084085A1 (en) * 2004-06-16 2006-04-20 Sinclair David A Methods and compositions for modulating Bax-mediated apoptosis
JP2006273834A (ja) * 2004-06-28 2006-10-12 Kao Corp Ａｍｐｋ活性化剤
WO2006001278A1 (ja) * 2004-06-28 2006-01-05 Kao Corporation Ａｍｐｋ活性化剤
WO2006004722A2 (en) * 2004-06-30 2006-01-12 Biomol Research Laboratories, Inc. Compositions and methods for selectively activating human sirtuins
US20060029642A1 (en) 2004-08-03 2006-02-09 Dusan Miljkovic Methods and compositions for improved chromium complexes
WO2006138418A2 (en) 2005-06-14 2006-12-28 President And Fellows Of Harvard College Improvement of cognitive performance with sirtuin activators
US20070149466A1 (en) * 2005-07-07 2007-06-28 Michael Milburn Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
ES2520017T3 (es) * 2005-09-28 2014-11-11 The Regents Of The University Of California Procedimiento de reducción de la presión sanguínea en individuos prehipertensos y/o individuos con síndrome metabólico
US7912716B2 (en) * 2005-10-06 2011-03-22 Sony Online Entertainment Llc Generating words and names using N-grams of phonemes
JP2007126390A (ja) * 2005-11-02 2007-05-24 Mercian Corp 血糖値低下剤
US7887848B2 (en) * 2006-05-31 2011-02-15 Interhealth Nutraceuticals, Inc. Nutraceutical treatments for diabetic and non-diabetic wound healing
US20100062087A1 (en) * 2006-06-02 2010-03-11 Interhealth Nutraceuticals, Inc. Nutraceutical Treatments for Diabetic and Non-Diabetic Wound Healing
JP5045879B2 (ja) * 2006-06-07 2012-10-10 株式会社龍泉堂 インスリン抵抗性の改善効果、体重増加の抑制効果、及び脂肪肝の予防及び改善効果を有する混合物
TW201002332A (en) * 2008-07-07 2010-01-16 Univ Nat Chunghsing Composition for preventing and controlling fatty liver disease
US8410284B2 (en) 2008-10-22 2013-04-02 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
WO2010051206A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US20100323031A1 (en) * 2009-06-22 2010-12-23 Glykon Technologies Group, Llc Synergistic combination to enhance blood glucose and insulin metabolism
JP2013520502A (ja) 2010-02-25 2013-06-06 メルク・シャープ・エンド・ドーム・コーポレイション 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
CA2826649C (en) 2011-02-25 2016-07-26 Merck Sharp & Dohme Corp. Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
US20140045746A1 (en) 2012-08-02 2014-02-13 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
JP2016516004A (ja) 2013-02-22 2016-06-02 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 抗糖尿病二環式化合物
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
US9421217B2 (en) 2014-06-12 2016-08-23 Four LLC Sweet taste receptor antagonist compositions
CN106491641A (zh) * 2016-10-28 2017-03-15 乌林奇 一种靶向防治脑血栓的药物活性组合物及应用
WO2018106518A1 (en) 2016-12-06 2018-06-14 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
IT201700032960A1 (it) * 2017-03-24 2018-09-24 Akademy Pharma S R L Composto nutraceutico per il trattamento dell’eccesso di peso e della moderata ipercolesterolemia e disglicemia
EP4156970A4 (en) * 2020-06-02 2024-06-19 Glykon Technologies Group, LLC. Reducing triglyceride levels and cortisol levels with pharmaceutical preparations

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3764692A (en) 1970-09-30 1973-10-09 Hoffmann La Roche Method of treating obesity
US4954492A (en) * 1983-07-08 1990-09-04 The William Seroy Group Synthetic GTF chromium material for decreasing blood lipid levels and process therefor
US4923855A (en) 1983-07-08 1990-05-08 The William Seroy Group Synthetic GTF chromium material and process therefor
US5194615A (en) 1983-07-08 1993-03-16 The William Seroy Group Synthetic GTF chromium nicotinate material and its preparation
JPS62236469A (ja) 1986-04-04 1987-10-16 Yasutake Hichi 低カロリ−飲食物
US5266560A (en) * 1988-06-03 1993-11-30 Thomas Research Corporation Pharmaceutical insulin-potentiating CR(III) complexes with GTF-like activity
US5543405A (en) 1993-10-22 1996-08-06 Keown; Wendy J. Composition and method for weight reduction and long term management of obesity
US5480657A (en) 1993-10-27 1996-01-02 Allen; Ann De Wees T. Composition comprising caffeine chromium and fructose for weight control and use thereof
US5612039A (en) 1994-03-14 1997-03-18 Nini E. Policappelli Dietary supplement
US5567424A (en) 1994-06-10 1996-10-22 Reliv International, Inc. Fiber, antioxidant, herbal and enzyme supplemented beverage composition for human consumption
US6352713B1 (en) 1999-12-01 2002-03-05 Drugtech Corporation Nutritional composition
US5536516A (en) 1994-08-24 1996-07-16 Renaissance Herbs, Inc. Hydroxycitric acid concentrate and food products prepared therefrom
US20040196181A1 (en) * 1994-09-22 2004-10-07 Huston Charles D. Method and apparatus for message display on a golf course
EP0714663A3 (en) 1994-11-28 1997-01-15 Lilly Co Eli Potentiation of drug responses by serotonin 1A receptor antagonists
WO1996036585A1 (en) 1995-05-15 1996-11-21 Sabinsa Corporation A new process for the production of potassium hydroxy citric acid, and compositions containing the potassium hydroxy citric acid
US5626849A (en) 1995-06-07 1997-05-06 Reliv International, Inc. Weight loss composition for burning and reducing synthesis of fats
IT1276253B1 (it) 1995-12-15 1997-10-27 Sigma Tau Ind Farmaceuti Composizione farmaceutica contenente l-carnitina o alcanoil l-carnitine per la prevenzione ed il trattamento di stati morbosi
US5716976A (en) 1996-03-13 1998-02-10 Bernstein; Richard K. Method of treatment for carbohydrate addiction
FI120290B (fi) 1996-12-30 2009-09-15 Mirador Res Oy Ltd Menetelmä, jonka avulla voidaan valmistaa sellaisia mausteseos-, ruoan ainesosa- ja elintarvikekoostumuksia, jotka alentavat seerumin kolesterolia
EP1021177A4 (en) 1997-02-04 2002-05-15 John V Kosbab COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF VASCULAR DEGENERATIVE DISEASES
US5962030A (en) 1997-03-07 1999-10-05 Akesis Pharmaceuticals, Inc. Dietary supplement and method of treatment for diabetic control
JP3736776B2 (ja) 1997-03-25 2006-01-18 宝ホールディングス株式会社 新規カルシウム組成物
US5981510A (en) 1997-04-15 1999-11-09 Yaizu Suisankagaku Industry Co., Ltd. Method for treating and improving diabetes
US5911992A (en) 1997-06-12 1999-06-15 A. Glenn Braswell Method for controlling weight with hypericum perforatum and garcinia cambogia
EP1011660A1 (en) 1997-07-14 2000-06-28 Inter-Health Nutraceuticals Incorporated Hydroxycitric acid compositions, pharmaceutical and dietary supplements and food products made therefrom, and methods for their use in reducing body weight
US5877171A (en) 1997-07-28 1999-03-02 Mcleod; Malcolm N. Method of treating pre-menstrual syndrome using chromium
US6160172A (en) 1997-08-27 2000-12-12 Vittal Mallya Scientific Research Foundation Soluble double metal salt of group IA and IIA of (-) hydroxycitric acid, process of preparing the same and its use in beverages and other food products without effecting their flavor and properties
CA2320368C (en) 1998-02-23 2007-08-21 Taiyo Kagaku Co., Ltd. Composition comprising theanine
US6048846A (en) 1998-02-26 2000-04-11 Cochran; Timothy M. Compositions used in human treatment
AU5142699A (en) 1998-07-31 2000-02-28 Mount Sinai Hospital Corporation Methods and compositions for increasing insulin sensitivity
US5905075A (en) 1998-08-28 1999-05-18 Ambi Inc. Chromium nicotinate compositions and uses thereof
US6413545B1 (en) 1998-09-01 2002-07-02 Access Business Group International Llc Diet composition and method of weight management
JP2002542152A (ja) 1999-02-18 2002-12-10 ビッタル・マルヤ・サイエンティフィック・リサーチ・ファウンデーション （−）ヒドロキシクエン酸の可溶性ｉａおよびｉｉａ族金属複塩
WO2000057729A2 (en) 1999-03-26 2000-10-05 Akesis Pharmaceuticals, Inc. Beverages for treatment of glucose metabolism disorders
US6207714B1 (en) * 1999-09-14 2001-03-27 Dallas L. Clouatre Methods and pharmaceutical preparations for improving glucose metabolism with (−)-hydroxycitric acid
US6447807B1 (en) 1999-09-14 2002-09-10 Dallas L. Clouatre Potassium (-)-hydroxycitric acid methods for pharmaceutical preparations for stable and controlled delivery
US20030220329A1 (en) 1999-09-17 2003-11-27 Duke University Method of improving beta-adrenergic receptor function
PL354684A1 (en) 1999-12-16 2004-02-09 Harry Siskind Nutritional composition, methods of producing said composition and methods of using said composition
US6291533B1 (en) 1999-12-22 2001-09-18 Vitamerica, Inc. Dietary supplements for each specific blood type
US7015250B2 (en) 2000-02-09 2006-03-21 Glykon Technologies Group, Llc Methods and pharmaceutical preparations for normalizing blood pressure with (-)-hydroxycitric acid
US6399089B1 (en) 2000-05-15 2002-06-04 A. Glenn Braswell Compositions and methods for regulating metabolism and balancing body weight
US6383482B1 (en) 2000-08-24 2002-05-07 Vitacost.Com, Inc. Weight loss composition containing green tea, hydroxycitric acid, 5-hydroxytryptophan, glucomannan, picolinate and lactobacillus
EP1357977B1 (en) * 2000-09-21 2004-07-21 Nutrition 21, Inc. Chromium containing compositions for the treatment of diabetes, the reduction of body fat, improvement of insulin sensitivity and reduction of hyperglycemia and hypercholesteremia
US6579866B2 (en) 2000-12-28 2003-06-17 Mccleary Larry Composition and method for modulating nutrient partitioning
US6420350B1 (en) 2001-01-18 2002-07-16 Goen Group, Inc. Weight loss product
IL158172A0 (en) 2001-03-30 2004-03-28 Interhealth Nutraceuticals Inc Pharmaceutical compositions containing (-)-hydroxycitric acid
US20040157929A1 (en) 2002-04-01 2004-08-12 Ohia Sunny E. Method for increasing serotonin levels in a person by administration of a composition incorporating(-)hydroxycitric acid, and related compositions thereof
US6476071B1 (en) 2001-05-07 2002-11-05 Dallas L. Clouatre Correcting polymorphic metabolic dysfunction with (−)-hydroxycitric acid
US6441041B1 (en) 2001-06-20 2002-08-27 Dallas L. Clouatre (-)-hydroxycitric acid for the prevention of osteoporosis
US6482858B1 (en) 2001-06-20 2002-11-19 Dallas L Clouatre (−)-hydroxycitric acid for wound healing and immunomodulation
US6638542B2 (en) 2001-09-20 2003-10-28 Nutricia N.V. Reducing appetite in mammals by administering procyanidin and hydroxycitric acid
US7119110B2 (en) 2001-10-05 2006-10-10 Interhealth Nutraceuticals Incorporated Method and composition for preventing or reducing the symptoms of insulin resistance syndrome
US20030119913A1 (en) 2001-12-20 2003-06-26 Ohia Sunny E. Method for increasing serotonin levels in a person by administration of a composition incorporating (-)-hydroxycitric acid, and related compositions thereof
WO2003092730A1 (en) 2002-04-30 2003-11-13 Unibar Corporation Hydroxycitric acid salt composition and method of making
US6967030B2 (en) * 2003-01-14 2005-11-22 Wright Jonathan V Formulation for insulin and glucose control
WO2004085462A2 (en) 2003-03-21 2004-10-07 Interhealth Nutraceuticals Incorporated Method and composition for decreasing ghrelin levels

Similar Documents

Publication Publication Date Title
JP2005513107A5 (enExample)
TWI455723B (zh) 納曲酮及安非他酮於治療超重或肥胖病患之用途
HRP20150353T1 (hr) Farmaceutski pripravak koji sadrži glp-1 agonist, inzulin i metionin
JP2004520436A5 (enExample)
JP2009525985A5 (enExample)
WO2001041770A3 (en) Nanoparticulate eplerenone compositions
JP2008524120A5 (enExample)
CA2301378A1 (en) Stabilized pharmaceutical composition of a nonsteroidal anti-inflammatory agent and a prostaglandin
RU2007104095A (ru) Применение твердой пероральной дозировочной композиции пролонгированного действия для приготовления лекарственных средств
WO2003090671A3 (en) Chromium compositions and methods for using the same for inhibiting drug-induced insulin resistance
MXPA04003233A (es) Metodo y composicion para prevenir o reducir los sintomas del sindrome de resistencia a la insulina.
Morelli et al. Alternative therapies: Part I. Depression, diabetes, obesity
JP2009518293A5 (enExample)
WO2004062557A3 (de) Pharmazeutische kombination aus telmisartan und atorvastatinph zur prophylaxe oder therapie von kardiovaskulären, kardiopulmonalen, pulmonalen oder renalen krankheiten
JP2007238598A5 (enExample)
JP2005525329A5 (enExample)
Stals et al. Acanthosis nigricans caused by nicotinic acid: case report and review of the literature
JP2009506978A5 (enExample)
ME02149B (me) FORMULACIJE l METODE ZA LEČENJE AMILOIDOZE
JP2011516544A5 (enExample)
WO1999017612A1 (en) Serotonin containing formulation for oral administration and method of use
TW200427447A (en) Method and composition for decreasing ghrelin levels
WO2004062729A8 (de) Pharmazeutische kombination zur prophylaxe oder therapie von kardiovaskulären, kardiopulmonalen, pulmonalen oder renalen krankheiten
JP2007509946A5 (enExample)
EP1033133A4 (en) COMPOSITION FOR TREATING DIABETES AND METHOD FOR TREATING DIABETES